Quick answer
Kymera Therapeutics, Inc. (KYMR) reported revenue of $39.2M and net loss of $311.4M for the fiscal year ended 2025-12-31, down 16.7% from $47.1M the year before, per its 10-K filed with the SEC on 2026-02-26.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $39.2M | -$311.4M | — |
| 2024 (FY ending 2024-12-31) | $47.1M | -$223.9M | — |
| 2023 (FY ending 2023-12-31) | $78.6M | -$147.0M | — |
| 2022 (FY ending 2022-12-31) | $46.8M | -$154.8M | — |
| 2021 (FY ending 2021-12-31) | $72.8M | -$100.2M | — |
| 2020 (FY ending 2020-12-31) | $34.0M | -$45.6M | — |
| 2019 (FY ending 2019-12-31) | $2.9M | -$41.2M | — |
Related
- KR revenue, net income and debt history (Kroger Co)
- KRYS revenue, net income and debt history (Krystal Biotech, Inc.)
- KVUE revenue, net income and debt history (Kenvue Inc.)
- L revenue, net income and debt history (Loews Corp)
- LAMR revenue, net income and debt history (Lamar Advertising Co/New)
- LDOS revenue, net income and debt history (Leidos Holdings, Inc.)
- LECO revenue, net income and debt history (Lincoln Electric Holdings Inc)
- LEN revenue, net income and debt history (Lennar Corp /New/)
Last updated 2026-10-16. Data only, not financial or tax advice.